Lv2
200 积分 2025-11-13 加入
PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
6个月前
已关闭
PT2.11.02 Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study
7个月前
已关闭
A Behavioral Economics Perspective on Tobacco Taxation
7个月前
已完结
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
8个月前
已完结
驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识(2023版)
8个月前
已关闭
教你如何读懂肺癌的病理检查报告
8个月前
已完结
Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium
9个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
9个月前
已完结
The development of Zongertinib for HER2-mutant NSCLC
9个月前
已完结
皖公网安备34019202002308
